Assessment of Variation in Immunosuppressive Pathway Genes Reveals TGFBR2 to Be Associated with Risk of Clear Cell Ovarian Cancer

Background: Regulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated with ovarian cancer.

Methods: In a population of 15,596 epithelial ovarian cancer (EOC) cases and 23,236 controls, we measured genetic associations of 1,351 SNPs in Treg cell pathway genes with odds of ovarian cancer and tested pathway and gene-level associations, overall and by histotype, for the 25 genes, using the admixture likelihood (AML) method. The most significant single SNP associations were tested for correlation with expression levels in 44 ovarian cancer patients.

Results: The most significant global associations for all genes in the pathway were seen in endometrioid ( p = 0.082) and clear cell ( p = 0.083), with the most significant gene level association seen with TGFBR2 ( p = 0.001) and clear cell EOC. Gene associations with histotypes at p < 0.05 included: IL12 ( p = 0.005 and p = 0.008, serous and high-grade serous, respectively), IL8RA ( p = 0.035, endometrioid and mucinous), LGALS1 ( p = 0.03, mucinous), STAT5B ( p = 0.022, clear cell), TGFBR1 ( p = 0.021 endometrioid) and TGFBR2 ( p = 0.017 and p = 0.025, endometrioid and mucinous, respectively).

Conclusions: Common inherited gene variation in Treg cell pathways shows some evidence of germline genetic contribution to odds of EOC that varies by histologic subtype and may be associated with mRNA expression of immune-complex receptor in EOC patients.

Citing Articles

Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Butler H, Saulat O, Guinn B Carcinogenesis. 2022; 43(3):183-189.

PMID: 35104328 PMC: 9036986. DOI: 10.1093/carcin/bgac012.

Inherited alterations of TGF beta signaling components in Appalachian cervical cancers.

Knobloch T, Peng J, Hade E, Cohn D, Ruffin 4th M, Schiano M Cancer Causes Control. 2019; 30(10):1087-1100.

PMID: 31435875 PMC: 6768402. DOI: 10.1007/s10552-019-01221-y.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell L, Cannioto R, Clay A, Etter J, Eng K, Liu S Cancer Epidemiol Biomarkers Prev. 2016; 26(3):420-424.

PMID: 27677730 PMC: 5500198. DOI: 10.1158/1055-9965.EPI-16-0631.

References

DeRycke M, Charbonneau B, Preston C, Kalli K, Knutson K, Rider D . Toward understanding the genetics of regulatory T cells in ovarian cancer. Oncoimmunology. 2013; 2(6):e24535. PMC: 3716752. DOI: 10.4161/onci.24535. View

Hendricks A, Dupuis J, Logue M, Myers R, Lunetta K . Correction for multiple testing in a gene region. Eur J Hum Genet. 2013; 22(3):414-8. PMC: 3925272. DOI: 10.1038/ejhg.2013.144. View

Zhao H, Shen J, Wang D, Guo Y, Gregory S, Medico L . Associations between gene expression variations and ovarian cancer risk alleles identified from genome wide association studies. PLoS One. 2012; 7(11):e47962. PMC: 3487879. DOI: 10.1371/journal.pone.0047962. View

Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T . CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005; 14(5):1269-73. View

Liu Y, Zheng P . FOXP3 and breast cancer: implications for therapy and diagnosis. Pharmacogenomics. 2007; 8(11):1485-7. DOI: 10.2217/14622416.8.11.1485. View

Zusman T, Lisansky E, Arons E, Anavi R, Bonnerot C, Sautes C . Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential. Int J Cancer. 1996; 68(2):219-27. DOI: 10.1002/(SICI)1097-0215(19961009)68:2<219::AID-IJC14>3.0.CO;2-5. View

Perez S, Karamouzis M, Skarlos D, Ardavanis A, Sotiriadou N, Iliopoulou E . CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007; 13(9):2714-21. DOI: 10.1158/1078-0432.CCR-06-2347. View

Sankararaman S, Sridhar S, Kimmel G, Halperin E . Estimating local ancestry in admixed populations. Am J Hum Genet. 2008; 82(2):290-303. PMC: 2664993. DOI: 10.1016/j.ajhg.2007.09.022. View

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

10.

Barnett B, Kryczek I, Cheng P, Zou W, Curiel T . Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005; 54(6):369-77. DOI: 10.1111/j.1600-0897.2005.00330.x. View

11.

Ogino S, Kawasaki T, Ogawa A, Kirkner G, Loda M, Fuchs C . TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007; 38(4):614-20. DOI: 10.1016/j.humpath.2006.10.005. View

12.

Barrington R, Pozdnyakova O, Zafari M, Benjamin C, Carroll M . B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J Exp Med. 2002; 196(9):1189-99. PMC: 2194107. DOI: 10.1084/jem.20021110. View

13.

Lee A, Tyrer J, Doherty J, Stram D, Kupryjanczyk J, Dansonka-Mieszkowska A . Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol. 2014; 136(3):542-8. PMC: 4892108. DOI: 10.1016/j.ygyno.2014.12.017. View

14.

Charbonneau B, Moysich K, Kalli K, Oberg A, Vierkant R, Fogarty Z . Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res. 2014; 2(4):332-40. PMC: 4000890. DOI: 10.1158/2326-6066.CIR-13-0136. View

15.

Gavalas N, Karadimou A, Dimopoulos M, Bamias A . Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol. 2011; 2010:791603. PMC: 3034919. DOI: 10.1155/2010/791603. View

16.

Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y . Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer. 2006; 120(6):1330-5. DOI: 10.1002/ijc.22443. View

17.

Zou W, Machelon V, Borvak J, Nome F, Isaeva T, Wei S . Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001; 7(12):1339-46. DOI: 10.1038/nm1201-1339. View

18.

Li J, Ji L . Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). 2005; 95(3):221-7. DOI: 10.1038/sj.hdy.6800717. View

19.

Duan S, Huang R, Zhang W, Bleibel W, Roe C, Clark T . Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008; 82(5):1101-13. PMC: 2651622. DOI: 10.1016/j.ajhg.2008.03.006. View

20.

Qin D, Wu J, Vora K, Ravetch J, Szakal A, Manser T . Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol. 2000; 164(12):6268-75. DOI: 10.4049/jimmunol.164.12.6268. View